

Dear Customer

With this letter, we would like to inform you about some updates within our test Portfolio for Autoimmune Diseases and Monitoring of Biopharmaceuticals.

NEWS & UPDATES TO OUR PORTFOLIO


SUBCLASS DETERMINATION of anti-GBM

Determination of anti-GBM of immunoglobulin G4 (IgG4) subclass is indicated in cases with weakly positive or negative results in the anti-GBM screening test when anti-GBM disease is still suspected. Anti-GBM IgG4 is predominantly found in younger women and may predict relapses indicating that these patients should be monitored closely.

This test is offered as an urgent test with result within 48 hours. In contrast, the clinical value of separate determination of anti-GBM of IgG1, IgG2 and IgG3 subclasses is low and will therefore no longer be available to request from our laboratory.


Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease.

(Ohlsson s. et al Am J Kidney Dis . 2014 Feb;63(2):289-93)



MONITORING OF BIOPHARMACEUTICALS

Since many years we offer both drug concentration, anti-drug antibody (ADA) level and neutralizing anti-drug antibody (NAb) levels (functional activity on *iLite*[®] cells) on all TNF α -inhibitors.



iLite[®] Functional Bioassay is based on a reporter gene system and offers a convenient and powerful way of measuring and quantifying drug potency, detecting neutralizing antibodies (NABs) and assessing immunogenicity. Reporter gene cell lines allow for detection of signal which is directly proportional to the induced function of your target drug.

We are also offering tests for drug concentration and anti-drug antibodies (ADA) for: vedolizumab, rituximab, ustekinumab, and tocilizumab. Drug concentration for: eculizumab and abatacept, as well as ADA levels for erythropoietin and natalizumab.

Due to lack of testing kits from our supplier we will no longer be able to measure drug concentration or anti-drug antibody level of omalizumab, nivolumab or trastuzumab.

For additional information, please see the enclosed Request Form.

REMOVAL OF PANELS & INDIVIDUAL TESTS

Since the following panels are offered by most hospital laboratories they will no longer be included in our specialized portfolio for autoimmune diagnostic testing

- **Celiac disease and extended analysis (512 & 578)**
- **Inflammatory Bowel disease (513 & 514)**

(Transglutaminase (IgA/IgG), Deamidated Gliadin (IgA/IgG), Total IgA quantification, ASCA (IgA/IgG).

The following tests are all included in the panel **024 ANA specificities** and will not be offered as individual tests: **Anti-nRNP (026), anti-Scl-70 (029) and anti-Jo-1 (030)**

The following tests will be removed from the portfolio due to low, or no demand:

Anti-Intrinsic factor (770), anti-TBM (097) and anti-KS (481)

ELECTRONIC TEST RESULTS - Get your test reports online!

As of October 2021, Wieslab AB and InfoSolutions Sverige AB have a collaboration that will enable the handling of test reports from Wieslab Diagnostic Services electronically in the InfoSolutions platform LabPortalen.

LabPortalen is a national and independent Swedish service for exchanging request forms and test results between laboratories and care providers. Today the service connects over 1000 different care providers with over 20 laboratories within Sweden and can be reached as well internationally with an English LabPortalen version.

Wieslab and InfoSolutions' collaboration means that you as a Wieslab customer now can access your test results in the LabPortalen. LabPortalen is a CE-marked medical product that provides a complete and secure system for delivering electronic test results.

An electronic test result from Wieslab will be displayed in LabPortalen, which can be accessed via a user account. The advantages of switching to a digital management are that you will receive the test results much faster, and that patient safety will be higher by not having to handle test results on paper.

Is your clinic interested in an account?

Please contact us for more information: Email: analysis.se@svarlifescience.com or telephone number: +46 40 53 76 60

ELECTRONIC TEST RESULTS
Get access to Wieslab Diagnostic Services test reports electronically in the InfoSolutions platform LabPortalen



URGENT TESTING - get your test results within 24-48 hours!

The following panels and individual tests can be ordered as Urgent Tests with a result within 24 or 48 hours.

- **PMN (Primary membranous nephropathy) (24h)**
- **Anti-GBM (IgG4) subclass determination (48h)**
- **Autoimmune Encephalitis (24h)**
- **Paraneoplastic syndrome/Cerebellar ataxia (24h)**
- **NMOSD/ADEM (Neuromyelitis Optica Spectrum Disorder) (24h)**
- **Neurofilament light (NfL) (48h)** (EDTA-plasma/serum/CSF)

WEBSITE & REQUEST FORMS

On our website you will find information about all our different tests and panels:

www.svarlifescience.com/services/wieslab-diagnostic-services

It is possible to download all our Request Forms, fill them in electronically and print out. You can also order printed copies from the website.

FREE OF CHARGE

- **EXPERT CONSULTANCY**
If you have questions about interpreting laboratory test results from us - contact us via email.
- **BIOBANK**
When consented by the patient, remaining test material is stored frozen up to five years after the analysis has been ordered. If you need us to further test a previously sent patient sample – contact our laboratory.

SEARCHING FOR A SPECIFIC MARKER OR A RESEARCH PARTNER?

Is the test you are looking for not on our Request Forms? Or are you looking for a partner for testing within a clinical trial or project? Take advantage of our expertise, flexible solutions and exceptional customer service.

PRESENTATION OF OUR PORTFOLIO

Do you want more information? We are happy to visit you for a presentation - at lunchtime or another desired time!

Mail: diagnostic.services@svarlifescience.com

Phone: +46 40 53 76 60

Monica Blixt

Sales Director Diagnostics

+46 708 862 810

monica.blixt@svarlifescience.com

Lina Tebbila

Product Manager

+46 730 934 804

lina.tebbila@svarlifescience.com

Rita Martins Olofsson

Head of Diagnostic Services

+46 730 453 041

rita.martinsolofsson@svarlifescience.com

Appendix: Request Forms; Autoimmune Diagnostics and Monitoring of Biopharmaceuticals, January 2022

Wieslab AB, a Svar Life Science company

Lundavägen 151
SE-212 24 Malmö
+46 40 53 76 60

P.O. Box 50117
SE-202 11 Malmö
Sweden

SVAR
WIESLAB